67 related articles for article (PubMed ID: 16526182)
1. [Calcium balance and regulation in schizophrenic patients treated with second generation antipsychotics].
Wyszogrodzka-Kucharska A; Rabe-Jabłońska J
Psychiatr Pol; 2005; 39(6):1157-71. PubMed ID: 16526182
[TBL] [Abstract][Full Text] [Related]
2. [Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics].
Wyszogrodzka-Kucharska A; Rabe-Jabłońska J
Psychiatr Pol; 2005; 39(6):1173-84. PubMed ID: 16526183
[TBL] [Abstract][Full Text] [Related]
3. [Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics--risperidone and olanzapine].
Wyszogrodzka-Kucharska A; Kunert-Radek J; Rabe-Jabłońska J
Psychiatr Pol; 2005; 39(6):1143-55. PubMed ID: 16526181
[TBL] [Abstract][Full Text] [Related]
4. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.
Savina I; Beninger RJ
Schizophr Res; 2007 Aug; 94(1-3):128-38. PubMed ID: 17560766
[TBL] [Abstract][Full Text] [Related]
5. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
[TBL] [Abstract][Full Text] [Related]
6. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
[TBL] [Abstract][Full Text] [Related]
7. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.
Ren XS; Lee AF; Huang YH; Hamed A; Herz L; Miller DR; Kazis LE
J Clin Pharm Ther; 2004 Oct; 29(5):471-81. PubMed ID: 15482392
[TBL] [Abstract][Full Text] [Related]
8. Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone.
Filaković P; Koić O; Laufer D; Radanović-Grgurić L; Degmecić D; Pozgain I
Coll Antropol; 2007 Dec; 31(4):1105-9. PubMed ID: 18217467
[TBL] [Abstract][Full Text] [Related]
9. Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.
Wu PL; Lane HY; Su KP
Psychiatry Clin Neurosci; 2006 Feb; 60(1):115-6. PubMed ID: 16472369
[No Abstract] [Full Text] [Related]
10. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
Hardy TA; Marquez E; Kryzhanovskaya L; Taylor CC; Cavazzoni P
J Clin Psychopharmacol; 2006 Aug; 26(4):405-8. PubMed ID: 16855460
[TBL] [Abstract][Full Text] [Related]
11. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
Rabinowitz J; Lichtenberg P; Kaplan Z; Mark M; Nahon D; Davidson M
Am J Psychiatry; 2001 Feb; 158(2):266-9. PubMed ID: 11156809
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.
Kinon BJ; Liu-Seifert H; Ahl J; Ahmed S; Baker RW
Ann N Y Acad Sci; 2004 Dec; 1032():295-6. PubMed ID: 15677433
[TBL] [Abstract][Full Text] [Related]
13. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
Svestka J; Synek O; Tomanová J; Rodáková I; Cejpková A
Neuro Endocrinol Lett; 2007 Dec; 28(6):881-8. PubMed ID: 18063941
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study.
Broerse A; Crawford TJ; den Boer JA
J Neuropsychiatry Clin Neurosci; 2002; 14(4):454-60. PubMed ID: 12426415
[TBL] [Abstract][Full Text] [Related]
15. [Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study].
Mayoral F; Montejo AL; Bousoño M; González-Torres MA; Olivares JM; Ros S; Sanjuán J; Escobar R; Lara N
Actas Esp Psiquiatr; 2006; 34(1):7-15. PubMed ID: 16525900
[TBL] [Abstract][Full Text] [Related]
16. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
[TBL] [Abstract][Full Text] [Related]
17. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients.
Smith RC; Lindenmayer JP; Bark N; Warner-Cohen J; Vaidhyanathaswamy S; Khandat A
Int J Neuropsychopharmacol; 2005 Jun; 8(2):183-94. PubMed ID: 15737248
[TBL] [Abstract][Full Text] [Related]
18. Effects of antipsychotics on the serum BDNF levels in schizophrenia.
Chen CC; Huang TL
Psychiatry Res; 2011 Oct; 189(3):327-30. PubMed ID: 21320726
[TBL] [Abstract][Full Text] [Related]
19. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
20. Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.
Lasser RA; Mao L; Gharabawi G
Schizophr Res; 2004 Feb; 66(2-3):163-7. PubMed ID: 15061249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
